Praxis Precision Medicines Showcases Epilepsy Innovations
![Praxis Precision Medicines Showcases Epilepsy Innovations](https://investorshangout.com/images/blog/ihnews-Praxis%20Precision%20Medicines%20Showcases%20Epilepsy%20Innovations.jpg)
Praxis Precision Medicines Highlights Epilepsy Innovations
BOSTON, Sept. 4, 2024 – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on transforming genetic insights into treatments for central nervous system (CNS) disorders, has announced its participation in the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress. The event will take place from September 7 to 11, 2024, bringing together experts in the field to discuss advancements in epilepsy research.
Steven Petrou, chief scientific officer and co-founder of Praxis, expressed enthusiasm about the company’s progress. "We are pleased to highlight the continued advancements across our epilepsy assets, including significant evidence generated in our elsunersen and relutrigine studies. We are actively enrolling registrational trials for both compounds and are excited to launch our ENERGY program with PRAX-628 soon," he stated.
Pivotal Presentations at the European Epilepsy Congress
At this prestigious event, Praxis will be making several presentations that showcase their innovative approaches to treating epilepsy. Attendees can connect with the Praxis team at booth #441 and learn about cutting-edge research findings.
Oral Presentation Schedule
An important oral presentation is scheduled for Tuesday, September 10, at 01:02 p.m. – 01:10 p.m. CEST, during the Pediatric Epileptology session in the Caravaggio venue.
Poster Presentations Overview
Additionally, Praxis will feature multiple poster presentations from September 8 to 10, 2024, during the afternoon sessions at the Forum venue. Key presentations include:
- P083: Pharmacokinetics, Tolerability and Cardiac Safety for PRAX-628, a Therapeutic for Focal Onset Seizures.
- P898: A Novel Antisense Oligonucleotide Treatment for Early Onset SCN2A Developmental and Epileptic Encephalopathy.
- P908: EMBOLD Clinical Trial of PRAX-562 for Developmental and Epileptic Encephalopathies.
- P074: A Translational Concordance Framework for Predicting Seizure Models.
- P339: EEG Composite Techniques for Detecting Drug Effects in Epilepsy.
Innovative Treatments for Epilepsy
Praxis is pioneering unique therapies such as relutrigine and PRAX-628, which target specific neurological channels to provide better patient outcomes. Relutrigine has shown promising results in reducing seizure activity in various mouse models and has displayed tolerability in Phase 1 studies. It has received Orphan Drug and Rare Pediatric Disease designations, underscoring its potential in treating severe developmental and epileptic encephalopathies.
Moreover, PRAX-628 is being developed as a once-daily oral treatment. Preclinical data highlight its superior efficacy compared to current treatments, positioning it as a potential best-in-class solution for managing focal seizures.
About Elsunersen (PRAX-222)
Another significant focus is on Elsunersen, an antisense oligonucleotide designed to decrease SCN2A gene expression, directly targeting early-onset SCN2A developmental and epileptic encephalopathy. Studies have indicated its capability to not only reduce seizures but also enhance overall functionality in affected patients. Elsunersen has earned both FDA Orphan Drug and Rare Pediatric Designations, reflecting its critical role in therapeutic strategies.
About Praxis Precision Medicines
Praxis Precision Medicines is devoted to pioneering therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. With a diverse portfolio that includes multiple clinical-stage candidates, Praxis continues to leverage genetic insights to develop innovative treatments for neurological disorders.
To learn more about their groundbreaking work and to keep updated with their latest developments, individuals are encouraged to visit the Pragmas website and follow them on social media platforms.
Frequently Asked Questions
1. What is the purpose of Praxis’s presentations at the Congress?
Praxis aims to showcase the latest advancements in their epilepsy research and highlight their innovative treatment options.
2. What are the key compounds being presented by Praxis?
Key compounds include relutrigine, PRAX-628, and Elsunersen, which target various forms of epilepsy and related disorders.
3. Where can attendees find Praxis during the Congress?
Attendees can visit Praxis at booth #441 for discussions and insights about their research.
4. What designations have been awarded to the compounds developed by Praxis?
Compounds like Relutrigine and Elsunersen have received Orphan Drug Designation and Rare Pediatric Disease Designation from regulatory agencies.
5. How does Praxis use genetic insights in their research?
Praxis translates genetic insights into the development of therapies aimed at correcting neuronal excitation-inhibition imbalances in CNS disorders.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Apple's Anticipated 'Glowtime' Event to Unveil Innovations
- Innovations Fueling Growth in the Sustainable Label Market
- Evoke Pharma to Showcase Innovations in Investment Conference
- Rugged Servers Market Growth Trends and Key Innovations
- AmpliTech Group Showcases 5G Solutions at MWC Events
- AMD to Showcase Innovations at Goldman Sachs Event
- Remitly to Showcase Innovations at Upcoming Conference
- GridGain to Showcase Real-Time Data Innovations at Conferences
- Banzai to Showcase Innovations at H.C. Wainwright Conference
- BiomX CEO to Showcase Innovations at Investment Conference
- Eisai Showcases New Cancer Research Data at ESMO 2024
- Sensei Biotherapeutics to Showcase Innovations at Key Events
- Ocular Therapeutix to Showcase Innovations at Upcoming Events
- U-tec Showcases Innovative Smart Home Solutions at IFA
- Beamr Imaging Ltd. Showcases Innovation at Key Conference
- atai Life Sciences to Showcase Innovations at Investment Conference
- Agricultural Equipment Market Growth and Innovations Ahead
- Cloud Storage Market Growth Forecast Showcases Major Trends
- Baseus Showcases Innovative Products at 2024 IFA Expo
- Amorepacific Museum Showcases Elmgreen & Dragset's Art Spaces
- OnPoint Showcases Innovative AR-AI Technology at Conference
- LG's OLED Technology Showcases Master Ink Artistry
- Iovance Biotherapeutics to Showcase Innovations in TIL Therapies
- Corvus Pharmaceuticals to Showcase Innovations at Investment Event
- Silexion Therapeutics to Showcase Innovations at Investment Conference
Recent Articles
- Ilegal Mezcal Launches Unique Reposado Caribbean Cask Finish
- NCICU Direct Admission Program Revolutionizes College Access
- TrustGrid Partners with Department of Air Force for Innovation
- John Bonasera Joins Blue Matter, Enhancing Strategic Expertise
- PennantPark Investment Corporation Declares $0.08 Monthly Dividend
- Sofwave Appoints Larry Laber as Executive VP of Sales
- The Dermatology Specialists Launch 50th Location with Free Screenings
- COVID-19 Therapeutics Market Expected to Surpass $16 Billion
- TeraWulf Provides Update on August 2024 Operations and Production
- SeaStar Medical Eliminates Long-Term Debt to Enhance Growth
- Midi Health and Mount Sinai Team Up for Menopause Care Access
- HP Overtakes Apple in Laptop Sales During Q1 of 2024
- Brazil's Central Bank: Credit Growth Remains Stable Amid Caution
- Volvo Cars Adjusts Electric Vehicle Goals Amid Market Changes
- Palo Alto Networks Completes Acquisition of IBM's QRadar Assets
- Denmark's Leading Pension Firm Partners with Omada for IGA
- PetSmart Announces Conference Call for Q2 2024 Financial Results
- APA Infrastructure Announces Cash Tender Offer for Senior Notes
- What If Media Group Fosters Innovation at LeadsCon Summit
- Osisko Gold Royalties Offers Insightful Asset Updates
- Context Therapeutics Welcomes Dr. Smith and Dr. Walker to Board
- Perricone Farms Strengthens Portfolio with Natalie's Juice Merger
- Aya Gold & Silver Unveils Encouraging Drill Results
- BioVaxys to Showcase Innovative Cancer Vaccination Data Soon
- AlphaGraphics Recognized Among 2024's Most Profitable Franchises